Alembic Pharmaceuticals Ltd Corporate Actions

Alembic Pharma’s Vadodara Plant Gets VAI Status from US FDA

 Copy Link

Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).

Alembic Pharma reports 23% decline in Q3 net profit

 Copy Link

EBITDA margin came in at 15.4% in the quarter under review as compared to 16.30% in the previous corresponding period.

Alembic Pharma gets USFDA approval for generic heart failure medication

 Copy Link

The authorised ANDA is a therapeutic equivalent of the reference-listed drug (RLD), Corlanor tablets, in the same 5 mg and 7.5 mg dosages.

Alembic Pharma gets USFDA approval hypertension drug

 Copy Link

These medications are also used to treat chronic stable angina and angina induced by coronary artery spasm.

Alembic Pharma Gets USFDA Approval for Diltiazem ER Capsules

 Copy Link

Alembic Pharmaceuticals continues to grow its footprint in the US, with this approval contributing to its robust portfolio of generic medications.

Alembic Pharma's Gujarat plant clears USFDA inspection

 Copy Link

The business stated that the authorised ANDA is therapeutically similar to the reference-listed drug product (RLD) Lastacaft Solution.

Alembic Pharma Shares Jump on USFDA Approval for Lamotrigine Tablets

 Copy Link

The approved Lamotrigine Extended-Release tablets are therapeutic equivalents of GlaxoSmithKline's Lamictal XR, with strengths of 200 mg, 250 mg, and 300 mg.

Alembic Pharmaceuticals Gets US FDA Approval for Dabigatran Etexilate Capsules

 Copy Link

Alembic Pharmaceuticals has got the final approval from USFDA for Dabigatran Etexilate Capsules, 110 mg.

Alembic Pharma's Luphenazine Tablets Get USFDA Nod

 Copy Link

Alembic has 210 ANDA approvals from the USFDA, including 182 final approvals and 28 tentative clearances.

Alembic Pharma receives USFDA nod for generic Selexipag Injection

 Copy Link

This certification allows a company to apply for approval of a generic drug before the patents of the brand-name drug expire.